资讯

Fierce Pharma1 小时
Europe's CHMP gives thumbs up to ExCellThera's blood cancer cell therapy Zemcelpro
In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...
Medscape2 小时
Europe Recommends Stem Cell Therapy for Blood Cancers
Zemcelpro provides an option for people with a hematologic malignancy who need a blood stem cell transplant but have no ...
The American Journal of Managed Care1 天
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS
Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...
Zacks Investment Research on MSN3 天
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...
BioSpace3 天
Roche, AbbVie’s Venclexta Stumbles Again, This Time in Myelodysplastic Syndromes
Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...
Experimental model for myelodysplastic syndromes uncovers genetic alterations to improve ...
Myelodysplastic syndromes (MDS) are a group of disorders that typically arise in adulthood, especially after the age of 70, ...
Stocktwits on MSN4 天
AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence
AbbVie (ABBV) said on Monday that its late-stage trial evaluating its drug Venetoclax in combination with Azacitidine in the ...
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For ...
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...
AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic ...
AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...